Each dose should be administered as a subcutaneous injection in the thigh,
abdomen, or upper arm.
- Check BNF or equivalent for UpToDate prescribing advice
Mode of action
- Glucagon like peptide 1 (GLP-1) analogues
- General used as add-on therapy for Type 2 diabetics unable to achieve an adequate HbA1c despite taking
maximally tolerated doses of metformin and or sulphonylureas
- T2DM [With Metformin/Sulfonylurea/Pioglitazone]
- Intermediate release Exenatide 5 micrograms BD for at least 1 month, then increased if necessary up to 10 micrograms BD, taken 1 hour before 2 main meals (at least 6 hours apart).
- Modified release (Weekly): Exenatide 2 mg once weekly
- T2DM [with basal Insulin alone or metformin/pioglitazone (or both)]
- Intermediate release: Exenatide 5 micrograms BD for at least 1 month, then increased if necessary up to 10 micrograms BD, taken within 1 hour before 2 main meals (at least 6 hours apart).
- Dose of concomitant sulfonylurea may need to be reduced.
- Rapid Reduction of Insulin can result in severe DKA
- Weight loss in elderly
- Stop in renal disease
- Moderate to severe renal disease
- Anorexia, constipation, diarrhoea, hypoglycaemia
- Slows gastric emptying